Is the FDA Too Cautious?
July 21, 2023
53 min
Full
308 of 464
July 21, 2023
Is the FDA Too Cautious?
0:00 / 53:15
Excerpt playback isn’t available for this episode — use the full-episode link.
Search the Record
Moment search isn’t open for this episode yet
When it opens, you’ll be able to type any phrase and jump straight to the second it was said.
Open to Debate Episodes Around July 21, 2023
Episode 308 of 464 — walk the feed in the order it was published.
53:15This episodeIs the FDA Too Cautious?
Summary
While the Food and Drug Administration (FDA) needs to approve safe and effective drugs as quickly as possible to patients who need them, it must also maintain the diligence and rigor necessary to prevent harm. Two health experts look at the pace of FDA approvals and argue about whether the agency is getting it right on keeping the public safe or stifling health innovations. Now we debate: Is the FDA Too Cautious?
Arguing Yes: Colin Hill, CEO & Co-Founder, Aitia
Arguing No: Peter Lurie, President and Executive Director of Center for Science in the Public Interest
Emmy award-winning journalist John Donvan moderates
Learn more about your ad choices. Visit podcastchoices.com/adchoices
Episode details and artwork are published by the show’s own feed. Sentinel plays short cited excerpts and links every episode back to its publisher.